Welcome to Markets Desk, where we break down what's moving markets and why.
Pfizer is making a serious play for the weight-loss space, and Wall Street is paying attention. The company's pipeline in the obesity category is drawing comparisons to the GLP-one wave that made Novo Nordisk and Eli Lilly household names. With the global market projected to hit one hundred billion dollars, Pfizer's late entry could prove strategically timed rather than late.
Shifting to Berkshire Hathaway, the firm trimmed its position in Mastercard, which always draws headlines given Buffett's long-standing affection for payments networks. But analysts are quick to note that Berkshire's portfolio decisions often reflect internal capital allocation needs rather than a verdict on the underlying company. Mastercard's fundamentals — transaction volume, margin structure, global penetration — remain largely intact.
And on the macro side, a new report from the Center for Economic and Policy Research is drawing sharp attention to the federal minimum wage, which has sat at seven dollars and twenty-five cents for seventeen consecutive years. Adjusted for inflation, that puts it at its lowest real value in roughly seventy years, a figure the report calls, plainly, a poverty wage. The political and consumer spending implications of that stagnation are hard to overstate.
That's the tape. Markets Desk, signing off the floor.
